NEW YORK, November 2, 2018 /PRNewswire/ --
According to MarketsandMarkets, the global infection control market is expected to reach USD 21.06
Billion by 2022, after having grown from USD 15.35 Billion in 2017. The market is also
expected to have a CAGR of 6.5%. The research indicates that the increasing use of e-beam sterilization, the rising importance of
single-use medical nonwovens and medical devices are increasing the demand for disinfection and sterilization products and
services. Based on end user, the global infection control market is segmented into hospitals & clinics, medical devices
companies, food industry, life sciences industry, pharmaceutical companies as well as other end users. Hospitals & clinics
are currently projected to register the highest CAGR during the forecast period. PCT Ltd. (OTC: PCTL), MEDNAX, Inc. (NYSE: MD),
Owens & Minor, Inc. (NYSE: OMI), CytoSorbents Corporation (NASDAQ: CTSO), Cerus Corporation (NASDAQ: CERS)
Research by Future Market Insights indicates that according to the U.S. Department of Health and Human Services, it is
estimated that one in every 20 infections are hospital-acquired diseases in the U.S. Similarly, improving the reimbursement
scenarios, regarding infection control in various nations such as U.S., Japan and U.K., will
further propel the growth of the infection control market. Likewise, an aging population will also augment the growth of the
market. It has been estimated by the World Health Organization (WHO) that the global elderly population is expected to reach
around 2 billion by 2050, having been around 524 million in 2010.
PCT Ltd. (OTC: PCTL) announced breaking news after the market close yesterday that, "with its New York-based representative, it has entered into a contractual agreement for the installation and
operation of two Annihilyzer® Infection Control Systems in a major Brooklyn hospital.
Installation of the systems is currently underway and near completion.
The Annihilyzer® Infection Control System is designed to prevent and reduce the occurrence of costly and often difficult to
treat hospital-associated infections (HAI's).
According to the Center for Disease Control & Prevention (CDC), 'On any given day, about
one in 25 hospital patients has at least one healthcare associated infection.' Quoted in Clinical Leadership & Infection
Control, Lynn White, MD, president of Patient Shield Concepts, said '…the estimated direct medical
cost of HAIs is around $10 billion annually, not including cost-shifting to private payers.
Including cost-shifting, HAIs may cost closer to between $35 billion and $45
billion for acute-care hospitals annually. The total direct, indirect and nonmedical social costs of HAIs are estimated at
around $96 billion to $147 billion annually, including loss of work,
legal costs and other patient factors.'
The Annihilyzer® Infection Control System produces on-site generated Electrochemically Activated cleaner and disinfectant
fluid solutions that allow hospitals to move away from traditional disinfectants that are toxic and can cause harm to the
housekeeping staff and patients. The Annihilyzer Infection Control System produces a cleaner and a disinfectant that are safe,
environmentally sound and greatly reduce the damage to furnishings and equipment caused by toxic chemicals, yet is effective
against HAI's like MRSA, VRE and C-diff. PCT Health's system tracks the life cycle of the cleaner and disinfectant and alerts the
user before the product is no longer at its optimum effectiveness.
The Annihilyzer® Fluid Tracking System can be customized to track employees to ensure that all proper cleaning and
disinfecting protocols are being performed during the cleaning process. This assists the hospital administration by supplying
valuable data regarding the who, what, when and how all areas of the hospital are cleaned and disinfected.
The Annihilyzer® System also incorporates the use of Electrostatic Smart Applicators that apply disinfectant to all surfaces.
Human error associated with improper application and coverage of disinfectant is no longer an issue as the electrostatic
applicators ensure that all surfaces are covered and wrapped with disinfectant. Fogging or misting systems are not time or cost
effective whereas the electrostatic application process is more thorough and takes less time, so room turnover is much faster.
The Annihilyzer® Infection Control System is very cost effective and performs well where other cleaning and disinfecting systems
sometimes fail.
For additional information about the Annihilyzer® Infection Control System, visit http://www.pcthealth.com
MEDNAX, Inc. (NYSE: MD) is a national health solutions partner based in Sunrise, Fla.
And is comprised of the nation's leading providers of physician services. MEDNAX, Inc. recently announced that it has partnered
with Pacira Pharmaceuticals, Inc. to address the ongoing use of opioids during, and after, cesarean surgery by launching a
national collaborative aimed at addressing the Quadruple Aim through the implementation of an Enhanced Recovery after Cesarean
Surgery (ERACS™) program. The collaborative will be multi-disciplinary in nature, engaging the expertise of maternal-fetal
medicine physicians, anesthesiologists, obstetricians and perioperative nurses to improve the patient experience as well as
maternal and infant health, reduce the total cost of care and enhance provider satisfaction. The ERACS™ program will encompass
comprehensive educational and clinical implementation pathways. The overarching goals will be to educate clinical teams, shorten
the length of postoperative hospital stays, reduce the use of opioid analgesics and improve postoperative pain control. In
addition, MEDNAX and Pacira will monitor a series of clinical quality, safety and value-based performance indicators including:
reduced serious maternal and infant morbidity, reduced postoperative nausea and vomiting, lower rate of surgical site infections,
lower rate of return to the operating room, lower rate of readmission to the hospital and lower total cost of care.
Owens & Minor, Inc. (NYSE: OMI) is a global healthcare solutions company with integrated technologies, products,
and services aligned to deliver significant and sustained value for healthcare providers and manufacturers across the continuum
of care. Owens & Minor announced earlier this year that it had completed the acquisition of the surgical and infection
prevention ("S&IP") business of Halyard Health, Inc., on April 30th, 2018, for
approximately USD 710 Million in cash, subject to certain adjustments as provided in the Amended
and Restated Purchase Agreement. With the acquisition of the Halyard S&IP business, a recognized leader in its segment, Owens
& Minor takes a significant step in transforming its business into a global healthcare solutions provider. This transaction
expands Owens & Minor's reach into new markets around the world, develops its presence in the medical products segment, and
opens new channels for growth. The acquisition will also add greater scale to Owens & Minor's existing own-brand product
portfolio and help to expand the company's addressable markets.
CytoSorbents Corporation (NASDAQ: CTSO) is a leader in critical care immunotherapy, specializing in blood purification.
Recently, CytoSorbents once again sponsored the 7th Annual Celebration of Sepsis Heroes event hosted by the Sepsis Alliance on
September 13th, 2018, in New York City at Marquee New
York (289 10th Avenue). The sold-out event recognizes individuals and organizations that are making a difference in sepsis
awareness. This year's honorees include Mr. Jay Towers, the University of
Michigan Post ICU Longitudinal Survivor Experience (UM-PULSE), Rooks County Health Center,
Ms. Jill Kogan Blake, and Ms. Sharon Hansen. In addition,
CytoSorbents will again sponsor the Roger Bone Award for Excellence in Sepsis Research, to be
awarded by the German Sepsis Society at this year's DIVI Critical Care Congress in Leipzig,
Germany, to recognize an outstanding publication in clinical sepsis research for young scientists in German-speaking
countries. Dr. Bone was a pioneer in understanding the connection between uncontrolled inflammation and organ failure in sepsis
pathology and one of the fathers of critical care immunotherapy. Dr. Phillip Chan, MD, PhD, Chief
Executive Officer of CytoSorbents stated, "Sepsis is the overzealous immune response to an infection, and remains one of the top
ten causes of death worldwide, despite the use of antibiotics and standard medical care. Only through a coordinated effort of
infection prevention, faster recognition, early antibiotic treatment, and aggressive control of deadly inflammation, can we turn
the tide on this lethal scourge. We are thankful that our CytoSorb therapy is being increasingly embraced around the world as a
powerful new weapon against sepsis."
Cerus Corporation (NASDAQ: CERS) is a biomedical products company focused in the field of blood transfusion
safety. Cerus Corporation recently announced that the U.S. Department of the Navy will implement pathogen-reduction for all
apheresis platelets collected at Navy Blood Donor Centers. The Bureau of Medicine and Surgery (BUMED) noted that with the recent
history with Zika Virus, Ebola, Chikungunya, Dengue, and Babesia, emerging pathogens continue to threaten the blood supply and
that the use of pathogen reduction technologies will preemptively address the risk due to emerging pathogens. All Navy Blood
Donor Centers are required to implement the policy to pathogen-reduce platelet components by December
31st, 2018. "We are pleased that the U.S. Navy is expanding the use of pathogen-reduction technology to treat
platelet components throughout its entire blood collection system," said William 'Obi' Greenman, Cerus' President and Chief
Executive Officer. "By fully adopting pathogen reduction, the U.S Navy Blood Program is providing our Nation's Sailors, Marines,
and their families around the globe access to platelets with reduced risk of transfusion-transmitted infection (TTI) from known
and emerging pathogens."
Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News,
Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company
Interviews. A pioneer in the financially driven digital space, video production and integration of social media,
FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination,
branding, marketing and advertising for third parties for corporate news and original content through our unique media platform
that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial
Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not
undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided
[exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into
media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials
for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the
information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting
high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com
does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along
with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our
unique financial newswire and media platform. For pct ltd. financial and corporate news dissemination, FinancialBuzz.com has been
compensated five thousand dollars by paradigm convergence. Our fees may be either a flat cash sum
or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities
are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion
of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR
advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post
information about any companies the information contained herein is not intended to be used as the basis for investment decisions
and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or
solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or
losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or
presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their
investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and
financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by
the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com
constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment
strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is
solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives,
other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and
legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless
of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be
reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please
visit: http://www.financialbuzz.com.
For further information:
info@financialbuzz.com
+1-877-601-1879
Url: http://www.FinancialBuzz.com
SOURCE FinancialBuzz.com